After one month of dual antiplatelet therapy (DAPT) with aspirin and ticagrelor (Brilinta) post-percutaneous coronary intervention for an acute coronary syndrome, dropping aspirin cut bleeding risk […]

Chelation therapy to remove potentially toxic levels of lead from the blood was not associated with a reduction in cardiovascular events in post-myocardial infarction (MI) patients […]

ATLANTA — Patients with acute coronary syndrome (ACS) who had a myocardial infarction or unstable angina and underwent percutaneous coronary intervention (PCI) had a 76% lower […]

Use of a mandibular advancement device (MAD) proved non-inferior to guideline-recommended continuous positive airway pressure (CPAP) to reduce blood pressure in patients with hypertension and obstructive […]

Use of a microaxial flow pump (Impella CP) with standard care led to a lower risk for death than standard care alone in patients with ST-elevation […]

Empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, did not show significant benefit in reducing a first heart failure (HF) hospitalization or death from any cause in […]

A human apolipoprotein A1 (ApoA1) product, which is the key constituent of high-density lipoprotein (HDL) cholesterol and removes excess lipid from atherosclerotic plaques, did not bring […]

ATLANTA, GA — Despite promise for improving heart failure (HF) in pilot studies, an interarterial shunt (IAS) device did not meet the primary composite efficacy endpoint […]